GlobeNewswire by notified

Van Lanschot Kempen publishes agenda for the 2022 annual general meeting

Share

Amsterdam/’s-Hertogenbosch, the Netherlands, 13April 2022

Van Lanschot Kempen today released the agenda and explanatory notes for its annual general meeting (AGM) on 25 May 2022.

The convening notice and the meeting’s agenda with explanatory notes are available from Shareholders meetings' 2022. The AGM will be held on 25 May 2022 in the Van Lanschot Tower in ‘s-Hertogenbosch and will start at 2.00 pm.

Media Relations: +31 20 354 45 85; mediarelations@vanlanschotkempen.com
Investor Relations: +31 20 354 45 90; investorrelations@vanlanschotkempen.com

About Van Lanschot Kempen
Van Lanschot Kempen, a wealth manager active in Private Banking, Investment Management and Investment Banking, with the aim of preserving and creating wealth, in a sustainable way, for both its clients and the society of which it is part. As a sustainable wealth manager with a long-term focus, Van Lanschot Kempen proactively seeks to prevent negative impact for all stakeholders and to create positive long-term financial and non-financial value. Listed at Euronext Amsterdam, Van Lanschot Kempen is the Netherlands’ oldest independent financial services company, with a history dating back to 1737. To fully leverage the potential of the Van Lanschot Kempen organisation for its clients, it provides solutions that build on the knowledge and expertise across its entire group and on its open architecture platform. Van Lanschot Kempen is convinced that it is able to meet the needs of its clients in a sustainable way by offering them access to the full range of its products and services across all its businesses.

For more information, please visit vanlanschotkempen.com

Important legal information and cautionary note on forward-looking statements
This press release may contain forward-looking statements on future events and developments. These forward-looking statements are based on the current insights, information and assumptions of Van Lanschot Kempen’s management about known and unknown risks, developments and uncertainties. Forward-looking statements do not relate strictly to historical or current facts and are subject to such risks, developments and uncertainties which by their very nature fall outside the control of Van Lanschot Kempen and its management.

Actual results, performances and circumstances may differ considerably from these forward-looking statements as a result of risks, developments and uncertainties relating to, but not limited to, (a) estimates of income growth, (b) costs, (c) the macroeconomic and business climate, (d) political and market trends, (e) interest rates and currency exchange rates, (f) behaviour of clients, competitors, investors and counterparties, (g) the implementation of Van Lanschot Kempen’s strategy, (h) actions taken by supervisory and regulatory authorities and private entities, (i) changes in law and taxation, (j) changes in ownership that could affect the future availability of capital, (k) changes in credit ratings and (l) evolution and economic and societal impact of the Covid-19 pandemic.

Van Lanschot Kempen cautions that forward-looking statements in this press release are only valid on the specific dates on which they are expressed, and accepts no responsibility or obligation to revise or update any information, whether as a result of new information or for any other reason.

This press release does not constitute an offer or solicitation for the sale, purchase or acquisition in any other way or subscription to any financial instrument and is not a recommendation to perform or refrain from performing any action.

This press release is a translation of the Dutch language original and is provided as a courtesy only. In the event of any disparities, the Dutch language version will prevail. No rights can be derived from any translation thereof.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Handelsinvest opdaterer prospektet23.4.2024 11:22:23 CEST | pressemeddelelse

Investeringsforeningen Handelsinvest Vestergade 8-16 8600 Silkeborg Tlf. 8989 2500 handelsinvest@jyskeinvest.dk www.handelsinvest.dk Nasdaq Copenhagen A/S Nikolaj Plads 6 1007 København K23. april 2024 Opdatering af prospektet i Handelsinvest Investeringsforeningen Handelsinvest har opdateret prospektet. Der er sket følgende opdateringer/ændringer: Opdatering af data på bestyrelsesmedlemmer.Tilføjelse af ”under overflytning” og ”under fusion” i de afdelingsspecifikke afsnit.Opdatering af investeringsstrategien i afdeling Nordamerika.Sproglige tilpasninger m.m. Det opdaterede prospekt kan findes på www.handelsinvest.dk Med venlig hilsen Lone Mørch Henrik Kragh Bestyrelsesformand Director

CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit23.4.2024 11:00:00 CEST | Press release

ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts. The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy. Presentation Details Title: Unlocking Tumor Eradication with Antibody-MHC T Cell Engagers Presenter: Leonardo Borras, Chief Scientific Officer Date: April 23, 2024 About CDR-Life CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to

Planlagt suspension i Sparinvest SICAV23.4.2024 10:54:57 CEST | pressemeddelelse

København, April 23, 2024 (GLOBE NEWSWIRE) -- Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeEquitas EUR RLU0362354549SSIEEURREthical Global Value EUR RLU0362355355SSIEGVEURREuropean Value EUR RLU0264920413SSIEUVEURRGlobal Value EUR RLU0138501191SSIGVEURR Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit eller Christian Rye Holm, CRH@nykredit.dk. Med venlig hilsen ID-Sparinvest, Filial af Sparinvest S.A, Luxembourg Dirk Schulze

Planlagt suspension i Investeringsforeningen Sparinvest23.4.2024 10:52:33 CEST | pressemeddelelse

Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeMix Aktier KL ADK0010014778SPIMAKLAValue Aktier KL ADK0010079631SPIVAKLAValue Europa KL ADK0060032571SPIVEUKLAValue Emerging Markets KL ADK0010304856SPIVEMKLABæredygtige Aktier Akk. KL ADK0060012896SPIBDAAKKKLAINDEX Dow Jones Sustainability World KLDK0010297464SPIDJWKLINDEX Emerging Markets KLDK0060300762SPIEMIKLINDEX Europa Growth KLDK0010297548SPIEUGKLINDEX Europa Small Cap KLDK0010297621SPIEUCKLINDEX Europa Value KLDK0010297704SPIEUVKLBæredygtige Aktier KL ADK0061294048SPIBDAGlobale Fokusaktier KL ADK0061293826SPIGFAMix Maksimum Risiko KL ADK0061551892SPIMMRIABæredygtige Value Aktier KL ADK0061551546SPIBDVAAMix Lav Risiko KL ADK0060623189SPIMLRKLAMix Mellem Risiko KL ADK0060623262SPIMMRKLAMix Høj Risiko KL ADK0060623346SPIMHRKLAMix Minimum Risiko KL ADK0060914901SPIMIXMINRISKKLA Eventuelle spørgsmål vedrørende

Delårsrapport for perioden 1. januar - 31. marts 202423.4.2024 10:47:40 CEST | pressemeddelelse

Bestyrelsen for Tivoli A/S har den 23. april 2024 behandlet og godkendt delårsrapporten for perioden 1. januar - 31. marts 2024. Tivoli åbnede sommersæsonen 22. marts, hvilket er tidligere end sidste år hvor sæsonen åbnede 31. marts. Dette påvirker resultatet for perioden som i hovedtræk er: En nettoomsætning på 90,4 mio. kr. mod 61,8 mio. kr. sidste år (+46%).Et resultat før af- og nedskrivninger (EBITDA) på -84,2 mio. kr. mod -96,7 mio. kr. sidste år.Et resultat før skat på -112,4 mio. kr. mod -126,1 mio. kr. sidste år.Et besøgstal på 221.000 mod 47.000 sidste år (+470%). ”Tivoli fortsætter den positive udvikling, vi så i 2023. Første kvartal 2024 tegner sig for et resultat svarende til det forventede, med bedre gæstetal og økonomisk resultat, end samme periode i 2023. Vi går ind i sommersæsonen med optimisme og en lang række attraktive tilbud til Tivolis gæster, som bl.a. kan se frem til en sommer med et overordentlig stærkt kulturprogram.” udtaler adm. direktør, Susanne Mørch Koch

HiddenA line styled icon from Orion Icon Library.Eye